A study to assess Immune checkpoint inhibitors-associated gout as immune-related adverse events and to explore potential pathophysiology
Latest Information Update: 18 Jan 2021
At a glance
- Drugs Ipilimumab (Primary) ; Cytotoxic T-lymphocyte antigen 4 inhibitors
- Indications Adenocarcinoma; Laryngeal cancer; Lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- 18 Jan 2021 New trial record